Growth Hormone Releasing Hormone Analog to Improve Nonalcoholic Fatty Liver Disease and Associated Cardiovascular Risk
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 30 Oct 2018
At a glance
- Drugs Tesamorelin (Primary)
- Indications Non-alcoholic fatty liver disease
- Focus Therapeutic Use
- 19 Oct 2018 Planned initiation date changed from 1 Oct 2018 to 15 Nov 2018.
- 31 Aug 2018 Biomarkers information updated
- 14 Aug 2018 Planned initiation date changed from 1 Apr 2018 to 1 Oct 2018.